Clinical trials: sponsored by Yuhan Corporation
Healthy Subjects (HS)
Bioequivalence Study Between YHP2508B and YHR2602 in Healthy Subjects
An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508B and YHR2602 in healthy subjects.
- Trial name
- NCT07912840
- Testing
- YHP2508B, YHR2602
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Subjects (HS)
Bioequivalence Study Between YHP2508A and YHR2601 in Healthy Subjects
An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508A and YHR2601 in healthy subjects
- Trial name
- NCT07912827
- Testing
- YHP2508A, YHR2601
- Where
- 2 sites in South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Subjects
Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects
An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508C and YHR2603 in healthy subjects
- Trial name
- NCT07584304
- Testing
- YHP2508C, YHR2603
- Where
- South Korea
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Participants
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
This is a randomized, double-blind, first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of YH35995
- Trial name
- NCT06517914
- Testing
- YH35995
- Where
- South Korea
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Subjects
Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers
A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2511 and YHP2511A in healthy volunteers
- Trial name
- NCT07470125
- Testing
- YHP2511, YHP2511A
- Where
- South Korea
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Subjects
Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects
A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2406 and YHR2501 in healthy volunteers
- Trial name
- NCT07265167
- Testing
- YHP2406, YHR2501
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Subject
Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects
A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2406 and YHR2501 in healthy volunteers
- Trial name
- NCT06920719
- Testing
- YHP2406, YHR2501
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Volunteer
Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects
A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2407 and YHR2502 in healthy volunteers
- Trial name
- NCT06926387
- Testing
- YHP2407, YHR2502
- Where
- South Korea
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Volunteers
Bioequivalence (BE) Study Between YHP2205 and YHR2401 in Healthy Volunteers
A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2205 and YHR2401 in healthy volunteers
- Trial name
- NCT06775522
- Testing
- YHP2205, YHR2401
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Atopic Healthy Subjects, Adult Subjects With Allergic Diseases
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases
This study aims to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles following multiple subcutaneous injections of YH35324 in healthy subjects or subjects with allergic diseases, who have…
- Trial name
- NCT05564221
- Testing
- YH35324, Omalizumab
- Where
- 9 sites in South Korea
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Adult Volunteers
Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.
This Clinical Trial is an open, randomized, fasted, single-dose, oral administration 2-sequence, 2-period crossover study to assess bioequivalence of lazertinib between two formulations in healthy adult volunteers.
- Trial name
- NCT05162274
- Testing
- Lazertinib(G001), Lazertinib(G002)
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Atopic Healthy Subjects, Adult Subjects with Mild Allergic Diseases
A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases
The purpose of this study is to evaluate the safety, tolerability, PK, and PD following subcutaneous injections of YH35324 in atopic healthy subjects or adult subjects with mild allergic diseases.
- Trial name
- NCT05061524
- Testing
- YH35324, Omalizumab
- Where
- 4 sites in South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Volunteers
Clinical Trial to Evaluate the PK Interactions of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy Volunteers
An open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetic interactions and safety after co-administration of YHR2402 and YHR2403 compared to the administration of YHR2402 independently in healthy…
- Trial name
- NCT06623526
- Testing
- YHR2402, YHR2402+YHR2403
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Volunteers
Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers
An open-label, randomized, single-dose, oral administration, 2-sequence, 2- period, crossover study to evaluate bioequivalence between YHP2305 and YHR2404 in healthy subjects
- Trial name
- NCT06613139
- Testing
- YHP2305, YHR2404
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Volunteers
Bioequivalence Study Between YHP2205 and YHR2401 in Healthy Volunteers
A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2205 and YHR2401 in healthy volunteers
- Trial name
- NCT06359626
- Testing
- YHP2205, YHR2401
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Hypertension
Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers
This is a phase 1, randomized, open label, single-dose, replicate crossover clinical trial to compare the safety and pharmacokinetics of YH22162 in healthy male volunteers.
- Trial name
- NCT03662620
- Testing
- Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg
- Where
- South Korea
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Volunteer, Renal Impairments
A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects
The purpose of this trial is to compare the pharmacokinetic characteristics and safety of YHD1119(Pregabalin SR 75mg) and YHD1119(Pregabalin SR 150mg) in subjects with renal impairment and healthy subjects.
- Trial name
- NCT05012436
- Testing
- YHD1119 75mg
- Where
- 2 sites in South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Volunteer
BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects
The objective of this study was to compare the pharmacokinetic profiles and bioequivalence of rivaroxaban after a single oral dose of rivaroxaban 2.5 mg tablet in healthy Korean subjects.
- Trial name
- NCT05418803
- Testing
- YHP1807 Tab. 2.5mg, YHR1901 Tab. 2.5mg
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy
The Exploration for Pharmacodynamics and Pharmacokinetics of YH4808 New Formulation in Healthy Subjects
The objective of this clinical trial is to explore pharmacodynamics and pharmacokinetics of YH4808 New Formulation in healthy volunteers.
- Trial name
- NCT02176668
- Testing
- YH4808 NF 100, YH4808 OF 200, YH4808 NF 200
- Where
- South Korea
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Volunteers
Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg
A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP1906 Tab. 5 mg and YHR1902 Tab. 5mg in healthy volunteers
- Trial name
- NCT04316065
- Testing
- YHP1906, YHR1902
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation